AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00156247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acitretin
Description: Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
Study NCT03748082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
Study NCT03748082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Reactive Hyperemia Index
Description: Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
Study NCT03748082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reactive Hyperemia Index
Description: Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
Study NCT03748082 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endothelial Cells Collection
Description: Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
Study NCT03748082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial Cells Collection
Description: Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
Study NCT06354504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure
Study NCT00886171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Social skills group will consist of one session (60 minutes) per week for 8 weeks
Study NCT00886171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Training
Description: Physical activity groups consist of one session (60 minutes) per week for 8 weeks
Study NCT02218411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercises routine based on the Otago exercise programme
Study NCT02738242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novus system
Description: The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
Study NCT00649025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FlutiForm 250/10
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00649025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKP-Fluticasone
Description: SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00649025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Fluticasone HFA
Description: Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT01483352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek DiaPort
Study NCT04200417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
Study NCT04200417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
Study NCT04200417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
Study NCT04200417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Embospheres
Description: Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
Study NCT02828709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
Study NCT03100630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7239361
Description: Specified dose on specified days
Study NCT01539915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT194
Description: Topically applied BCT194 cream (0.5%)
Study NCT05047003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EyeBOX Model EBX-4 (Portable version)
Description: The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
Study NCT00320112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocal Diabetes Peer Support Program
Description: participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
Study NCT00320112 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nurse Case management
Description: patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
Study NCT00320112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group outpatient counseling visits
Description: Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
Study NCT02693210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
Study NCT02693210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Participants will receive >= 10 mg/week methotrexate orally up to 24 weeks
Study NCT02693210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive >= 10 mg/week methotrexate orally up to 24 weeks
Study NCT02693210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cyclophosphamide
Description: Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
Study NCT02693210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Cyclophosphamide
Description: Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
Study NCT02693210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Participants will receive weekly oral placebo in place of Methotrexate
Study NCT02693210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Rituximab
Description: Participants will receive placebo in place of rituximab on days 1 and 15
Study NCT02693210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive 1g infusions of rituximab on Days 1 and 15
Study NCT04088760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)
Description: The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
Study NCT03488186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules
Description: 24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
Study NCT03488186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole Capsules
Description: 24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
Study NCT01492894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins/Tacrolimus
Description: Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
Study NCT01492894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Change from current calcineurin inhibitor to Sirolumus
Study NCT02766075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised TAVR Exercise Program
Description: Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait \& Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
Study NCT03095222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
Study NCT03095222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Standard of care for pain management.
Study NCT02665013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored
Description: Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
Study NCT02665013 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Untailored
Description: Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
Study NCT01825993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-BUPIVACAINE ; MORPHINE
Study NCT01825993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORPHINE
Study NCT01997203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D was given to 50 patients (HCV under treatment)
Study NCT03973177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenol Injection
Description: 6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
Study NCT03973177 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone Injection
Description: Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
Study NCT02996656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Antibiotic that will be give before a Trauma or elective open shoulder surgery
Study NCT02996656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Antibiotic that will be give before a Trauma or elective open shoulder surgery
Study NCT01203878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Administered 4 weeks after completion of imiquimod therapy
Study NCT01203878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
Study NCT01203878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
Study NCT02769637 — intervention group
Intervention type: DRUG
Intervention: PPI treatment
Description: PPI treatment or no PPI treatment
Study NCT01498848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cooking oils
Description: Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
Study NCT03883906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs)
Description: VSTs will be infused into stem cell transplant recipients
Study NCT04219566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS
Description: Non-invasive electrical vestibular nerve stimulation
Study NCT04219566 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo device
Description: Sham non-invasive electrical vestibular nerve stimulation
Study NCT01001845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Thistle extract
Description: 1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
Study NCT01001845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vit E
Description: 200 mg twice daily for 3 weeks
Study NCT01001845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vit E + Milk Thistle extract
Description: 200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
Study NCT03124966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter sensor
Study NCT00002725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Study NCT00002725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT02274129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healing cap II
Description: Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
Study NCT02188641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Study NCT02188641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study NCT02188641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet and Exercise
Study NCT02188641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Lifestyle (Control) Group
Study NCT02837757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue samples
Study NCT06176287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implantation with high torque
Description: Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
Study NCT06176287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implantation with low torque
Description: Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
Study NCT03119935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amflow
Description: Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
Study NCT03119935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu bag
Description: Participants ventilated the simulated patients by ambu bag
Study NCT02441478 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: functional magnetic resonance imaging exam
Study NCT02441478 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging exam
Study NCT03615300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum NGAL
Description: serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
Study NCT03006419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Standard induction therapy
Study NCT03006419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Induction therapy
Study NCT03486990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.
Study NCT01221376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
Study NCT01735630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005
Study NCT01735630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02463695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cortical vestibular evoked potentials (CVEPs)
Description: CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
Study NCT02463695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cortical vestibular evoked potentials (CVEPs)
Description: CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
Study NCT00795015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin regular IV infusion
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
Study NCT00795015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV insulin infusion
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
Study NCT01288131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine combine with mycophenolate mofetil
Description: Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
Study NCT01288131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide + pred
Description: Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day